Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis

Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis

<p>Abstract</p> <p>Background</p> <p>Pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) often receive intravenous liposomal amphotericin B (L-AmB) as antifungal prophylaxis. There are no guidelines for antifungal prophylaxis in child...

Full description

Bibliographic Details
Main Authors:	Döring Michaela, Hartmann Ulrike, Erbacher Annika, Lang Peter, Handgretinger Rupert, Müller Ingo
Format:	Article
Language:	English
Published:	BMC 2012-07-01
Series:	BMC Infectious Diseases
Subjects:	Caspofungin Liposomal amphotericin B Antifungal prophylaxis Pediatric patients Allogeneic stem cell transplantation
Online Access:	http://www.biomedcentral.com/1471-2334/12/151

Similar Items

Antifungal activity of caspofungin in experimental infective endocarditis caused by Candida albicans
by: Gerardo Becerra Victorio, et al.

Growth and Antifungal Resistance of the Pathogenic Yeast, <i>Candida Albicans</i>, in the Microgravity Environment of the International Space Station: An Aggregate of Multiple Flight Experiences
by: Sheila Nielsen, et al.
Published: (2021-03-01)

Assessment and Development of the Antifungal Agent Caspofungin for Aerosolized Pulmonary Delivery
by: Iching G. Yu, et al.
Published: (2021-04-01)

Isolation and antifungal susceptibility testing of Trichosporon asahii in Ceará, Brazil
by: Everardo Albuquerque Menezes, et al.
Published: (2012-02-01)

Osteoarticular Candida Infection: Report of Three Cases and Literature Review of 44 Patients
by: Firdevs AKSOY, et al.
Published: (2019-12-01)

Prophylactic use of liposomal amphotericin B in children and adolescents undergoing allogeneic hematopoietic cell transplantation: A 10-years single center experience
by: Laura G.Y. Rotte, et al.
Published: (2024-12-01)

Antifungal Prophylaxis in Solid Organ Transplant Recipients
by: Şebnem ŞENOL, et al.
Published: (2015-12-01)

Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature
by: Kofla G, et al.
Published: (2011-04-01)

Evaluating the Inappropriate Prescribing and Utilization of Caspofungin, a Four-Year Analysis at a Teaching Hospital in Saudi Arabia
by: Abdulwahab Aldrees, et al.
Published: (2021-12-01)

Antifungal Resistance in <i>Candida auris</i>: Molecular Determinants
by: María Guadalupe Frías-De-León, et al.
Published: (2020-09-01)

Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study
by: Peipei Ye, et al.
Published: (2022-05-01)

Absence of clinically relevant effect of caspofungin on cyclosporin pharmacokinetics
by: C Sanz-Rodriguez, et al.
Published: (2005-11-01)

Culture media influences Candida parapsilosis growth, susceptibility, and virulence
by: Betsy V. Arévalo-Jaimes, et al.
Published: (2023-12-01)

Efficacy and Safety of Combination Antifungals as Empirical, Preemptive, and Targeted Therapies for Invasive Fungal Infections in Intensive-Care Units
by: Yang Q, et al.
Published: (2022-09-01)

Antifungal Susceptibility of Oral <i>Candida</i> Isolates from Mother-Infant Dyads to Nystatin, Fluconazole, and Caspofungin
by: Naemah Alkhars, et al.
Published: (2023-05-01)

Epidemiology and Antifungal Susceptibility of Candida Species Isolated from 10 Tertiary Care Hospitals in Iran
by: Parisa Badiee, et al.
Published: (2022-12-01)

Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCT
by: Milo Gatti, et al.
Published: (2024-07-01)

Minocycline is a promising candidate as a combination therapy with caspofungin for drug-resistant Candida
by: Kazuhiro Itoh, et al.
Published: (2024-09-01)

The Effect of the COVID-19 Epidemic on the Prevalence of Opportunistic Fungal Infections and the Consumption of Antifungal Drugs in Patients Hospitalized in Abadan Hospitals
by: H Mojiri Forushani, et al.
Published: (2024-03-01)

Caspofungin-Induced Cardiotoxicity in Patients Treating for Candidemia
by: Roya Sattarzadeh Badkoubeh, et al.
Published: (2022-08-01)

Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association
by: Andrea Duminuco, et al.
Published: (2021-11-01)

Intermittent micafungin dosing schedule in pediatric oncology patients ‐ safe for outpatient parenteral antimicrobial therapy?
by: Jade A. Fox, et al.
Published: (2024-12-01)

Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis
by: Irina Ullmann, et al.
Published: (2022-06-01)

Peripheral Candidal Suppurative Thrombophlebitis Successfully Treated with Caspofungin in a Bariatric Surgery Patient
by: Özgür GÜNAL, et al.
Published: (2012-12-01)

Brilacidin, a novel antifungal agent against Cryptococcus neoformans
by: Camila Diehl, et al.
Published: (2024-07-01)

New Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis
by: Noelia Pérez-González, et al.
Published: (2021-12-01)

OUTCOME OF CANDIDA PARAPSILOSIS COMPLEX INFECTIONS TREATED WITH CASPOFUNGIN IN CHILDREN
by: İlker Devrim, et al.
Published: (2016-09-01)

Susceptibility to caspofungin is regulated by temperature and is dependent on calcineurin in Candida albicans
by: Lijun Zheng, et al.
Published: (2023-12-01)

[Clinical and juridical aspects of management of neonates with invasive fungal infections] [Article in Italian] • Aspetti clinici e giuridici della gestione del neonato con infezioni fungine invasive
by: Vassilios Fanos, et al.
Published: (2012-10-01)

Caspofungin-Loaded Formulations for Treating Ocular Infections Caused by <i>Candida</i> spp.
by: Noelia Pérez-González, et al.
Published: (2023-04-01)

The Prevalence of Antifungal Agents Administration in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Retrospective Study
by: Mona Kargar, et al.
Published: (2013-07-01)

The Prevalence of Antifungal Agents Administration in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study
by: Mona Kargar, et al.
Published: (2013-09-01)

Antifungal prophylaxis in stem cell transplantation centers in Turkey
by: Hamdi Akan
Published: (2011-12-01)

Antifungal prophylaxis in stem cell transplantation centers in Turkey
by: Hamdi Akan
Published: (2011-12-01)

Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience
by: Alessandro Busca, et al.
Published: (2022-01-01)

VZV Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation in Children: When to Stop?
by: Eva deBerranger, et al.
Published: (2024-11-01)

Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study
by: Dukhee Nho, et al.
Published: (2023-09-01)

Synergism between the Antidepressant Sertraline and Caspofungin as an Approach to Minimise the Virulence and Resistance in the Dermatophyte <i>Trichophyton rubrum</i>
by: Carlos H. Lopes Rocha, et al.
Published: (2022-08-01)

Are Systemic Voriconazole and Caspofungin Ototoxic? An Experimental Study with Rats
by: Emine Aydın, et al.
Published: (2012-09-01)

Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis
by: Martyna Wlodarczyk, et al.
Published: (2024-03-01)